Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

Brigham EF, Johnston TH, Brown C, Holt JDS, Fox SH, Hill MP, Howson PA, Brotchie JM, Nguyen JT.

J Pharmacol Exp Ther. 2018 Nov;367(2):373-381. doi: 10.1124/jpet.118.247650. Epub 2018 Aug 7.

PMID:
30087157
2.

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM.

Neuropharmacology. 2018 Jun 1. pii: S0028-3908(18)30270-3. doi: 10.1016/j.neuropharm.2018.05.035. [Epub ahead of print] Review.

PMID:
29907424
3.

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.

Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.

PMID:
29197517
5.

Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.

Ma Y, Johnston TH, Peng S, Zuo C, Koprich JB, Fox SH, Guan Y, Eidelberg D, Brotchie JM.

Mov Disord. 2015 Aug;30(9):1283-8. doi: 10.1002/mds.26302.

6.

The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.

Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM.

Neuropharmacology. 2015 Oct;97:306-11. doi: 10.1016/j.neuropharm.2015.05.033. Epub 2015 Jun 10.

PMID:
26071982
7.

Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.

Huot P, Johnston TH, Fox SH, Brotchie JM.

Synapse. 2015 Mar;69(3):99-102. doi: 10.1002/syn.21801.

PMID:
25559284
8.

L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.

Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM.

Behav Pharmacol. 2015 Feb;26(1-2):101-8. doi: 10.1097/FBP.0000000000000096.

PMID:
25303957
9.

UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

Neuropharmacology. 2014 Jul;82:76-87. doi: 10.1016/j.neuropharm.2014.01.012. Epub 2014 Jan 18.

PMID:
24447715
10.

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.

Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW.

Mov Disord. 2013 Oct;28(12):1675-82. doi: 10.1002/mds.25625. Epub 2013 Sep 3.

11.

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM.

Neuropharmacology. 2013 Oct;73:337-47. doi: 10.1016/j.neuropharm.2013.06.005. Epub 2013 Jun 14.

PMID:
23770260
12.

Alternating hemiplegia of childhood-related neural and behavioural phenotypes in Na+,K+-ATPase α3 missense mutant mice.

Kirshenbaum GS, Dawson N, Mullins JG, Johnston TH, Drinkhill MJ, Edwards IJ, Fox SH, Pratt JA, Brotchie JM, Roder JC, Clapcote SJ.

PLoS One. 2013;8(3):e60141. doi: 10.1371/journal.pone.0060141. Epub 2013 Mar 20.

13.

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.

Pharmacol Rev. 2013 Jan 10;65(1):171-222. doi: 10.1124/pr.111.005678. Print 2013 Jan. Review.

14.

Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.

Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM.

Eur J Neurosci. 2013 Mar;37(5):831-8. doi: 10.1111/ejn.12093. Epub 2013 Jan 3.

PMID:
23281915
15.

The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.

Huot P, Johnston TH, Gandy MN, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

PLoS One. 2012;7(9):e45587. doi: 10.1371/journal.pone.0045587. Epub 2012 Sep 20.

16.

A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.

Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E.

Mov Disord. 2012 Sep 15;27(11):1373-8. doi: 10.1002/mds.25133. Epub 2012 Sep 13. Review.

PMID:
22976821
17.

RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.

Johnston TH, Huot P, Damude S, Fox SH, Jones SW, Rusche JR, Brotchie JM.

Parkinsonism Relat Disord. 2013 Feb;19(2):260-4. doi: 10.1016/j.parkreldis.2012.07.001. Epub 2012 Aug 14.

PMID:
22901956
18.

L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.

Neuropharmacology. 2012 Oct;63(5):829-36. doi: 10.1016/j.neuropharm.2012.06.012. Epub 2012 Jun 18.

PMID:
22722022
19.

L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM.

J Pharmacol Exp Ther. 2012 Aug;342(2):576-85. doi: 10.1124/jpet.112.195693. Epub 2012 May 22.

20.

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.

Huot P, Johnston TH, Visanji NP, Darr T, Pires D, Hazrati LN, Brotchie JM, Fox SH.

Mov Disord. 2012 May;27(6):735-42. doi: 10.1002/mds.24964. Epub 2012 Mar 14.

PMID:
22419526

Supplemental Content

Loading ...
Support Center